🚀 VC round data is live in beta, check it out!
CR Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for CR Pharmaceutical and similar public comparables like Laboratorios Rovi, Dong-E-E-Jiao, Dianthus Therapeutics, Changchun High-Tech and more.
CR Pharmaceutical Overview
About CR Pharmaceutical
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2024, the medical distribution business accounts for 82.8% of its total revenue. CR Pharma’s manufacturing business, 18.0% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.
Founded
2007
HQ
Employees
72.7K
Website
Financials (LTM)
EV
$10B
CR Pharmaceutical Financials
CR Pharmaceutical reported last 12-month revenue of $40B and EBITDA of $2B.
In the same LTM period, CR Pharmaceutical generated $7B in gross profit, $2B in EBITDA, and $625M in net income.
Revenue (LTM)
CR Pharmaceutical P&L
In the most recent fiscal year, CR Pharmaceutical reported revenue of $38B and EBITDA of $2B.
CR Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $40B | XXX | $38B | XXX | XXX | XXX |
| Gross Profit | $7B | XXX | $6B | XXX | XXX | XXX |
| Gross Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $625M | XXX | $491M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CR Pharmaceutical Stock Performance
CR Pharmaceutical has current market cap of $5B, and enterprise value of $10B.
Market Cap Evolution
CR Pharmaceutical's stock price is $0.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $5B | -1.7% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCR Pharmaceutical Valuation Multiples
CR Pharmaceutical trades at 0.2x EV/Revenue multiple, and 3.9x EV/EBITDA.
EV / Revenue (LTM)
CR Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, CR Pharmaceutical has market cap of $5B and EV of $10B.
Equity research analysts estimate CR Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CR Pharmaceutical has a P/E ratio of 8.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 3.9x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBIT | 4.9x | XXX | 4.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.5x | XXX | 1.6x | XXX | XXX | XXX |
| P/E | 8.2x | XXX | 10.4x | XXX | XXX | XXX |
| EV/FCF | (37.2x) | XXX | 4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CR Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CR Pharmaceutical Margins & Growth Rates
CR Pharmaceutical's revenue in the last 12 month grew by 6%.
CR Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
CR Pharmaceutical's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CR Pharmaceutical's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
CR Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | (1%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CR Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CR Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Rovi | XXX | XXX | XXX | XXX | XXX | XXX |
| Dong-E-E-Jiao | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Changchun High-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Apellis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CR Pharmaceutical M&A Activity
CR Pharmaceutical acquired XXX companies to date.
Last acquisition by CR Pharmaceutical was on XXXXXXXX, XXXXX. CR Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CR Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCR Pharmaceutical Investment Activity
CR Pharmaceutical invested in XXX companies to date.
CR Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. CR Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CR Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CR Pharmaceutical
| When was CR Pharmaceutical founded? | CR Pharmaceutical was founded in 2007. |
| Where is CR Pharmaceutical headquartered? | CR Pharmaceutical is headquartered in China. |
| How many employees does CR Pharmaceutical have? | As of today, CR Pharmaceutical has over 72K employees. |
| Is CR Pharmaceutical publicly listed? | Yes, CR Pharmaceutical is a public company listed on HKEX. |
| What is the stock symbol of CR Pharmaceutical? | CR Pharmaceutical trades under 03320 ticker. |
| When did CR Pharmaceutical go public? | CR Pharmaceutical went public in 2016. |
| Who are competitors of CR Pharmaceutical? | CR Pharmaceutical main competitors are Laboratorios Rovi, Dong-E-E-Jiao, Dianthus Therapeutics, Changchun High-Tech. |
| What is the current market cap of CR Pharmaceutical? | CR Pharmaceutical's current market cap is $5B. |
| What is the current revenue of CR Pharmaceutical? | CR Pharmaceutical's last 12 months revenue is $40B. |
| What is the current revenue growth of CR Pharmaceutical? | CR Pharmaceutical revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of CR Pharmaceutical? | Current revenue multiple of CR Pharmaceutical is 0.2x. |
| Is CR Pharmaceutical profitable? | Yes, CR Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CR Pharmaceutical? | CR Pharmaceutical's last 12 months EBITDA is $2B. |
| What is CR Pharmaceutical's EBITDA margin? | CR Pharmaceutical's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of CR Pharmaceutical? | Current EBITDA multiple of CR Pharmaceutical is 3.9x. |
| What is the current FCF of CR Pharmaceutical? | CR Pharmaceutical's last 12 months FCF is ($261M). |
| What is CR Pharmaceutical's FCF margin? | CR Pharmaceutical's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of CR Pharmaceutical? | Current FCF multiple of CR Pharmaceutical is (37.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.